Az oklacitinibbel kapcsolatos tapasztalatok a bevezetést követő 10 év elteltével : Irodalmi összefoglaló = Oclacitinib for 10 years – Efficacy and safety : Literature review

Jerzsele, Ákos and Varga, Zsolt (2025) Az oklacitinibbel kapcsolatos tapasztalatok a bevezetést követő 10 év elteltével : Irodalmi összefoglaló = Oclacitinib for 10 years – Efficacy and safety : Literature review. MAGYAR ÁLLATORVOSOK LAPJA, 147 (11). pp. 643-659. ISSN 0025-004X

Text 643_659_Jerzsele_Gyogyszertan.pdf - Published Version Restricted to Repository staff only Download (1MB) | Request a copy

Abstract

A szerzők a 2013-ban az USA-ban, ill. 2014-ben az Európában bemutatott, a Janus-kináz-gátlók (JAK-gátlók) csoportjába tartozó, szájon át adható, a kutyák atópiás és allergiás bőrgyulladásának, ill. egyéb, viszketéssel járó kórképeinek kezelésére alkalmazható hatóanyagot, az oklacitinibet mutatják be. Részletesen tárgyalják a kutyák allergiás/atópiás bőrgyulladásának kórélettanát, a citokinek és a JAK-enzim szerepét a betegség patomechanizmusában, ill. az elmúlt több, mint 10 év során megjelent számos szakcikk elemzésével írnak a hatóanyag hatásmechanizmusáról, farmakokinetikai tulajdonságairól és a készítmény biztonságosságáról. | The purpose of this literature review is to summarize, based on articles published over the past 10 years, the accumulated knowledge on the mechanism of action, pharmacokinetics, and safety of oclacitinib maleat, a JAK-inhibitor that was introduced in USA in 2013 and then in 2014 in Europe for the treatment of allergodermatitis and atopic dermatitis of dogs. Atopic dermatitis is a severe, frequently occurring skin disease in dogs.The authors also discuss the pathophysiology of allergic/atopic dermatitis in dogs, the role of citokins and JAK enzymes in the pathomechanism of the disease. Oclacitinib - thanks to its several important advantages concerning efficacy, pharmacokinetics and safety compared to conventional therapies used for this disease - opened a new perspective in the treatment of allergic and atopic dermatitis of dogs. The authors present the active substance’s antiinflammatory, antipruritic and antiallergic effects as the pharmacological result of the mechanism of action. They analyze numerous studies related to the pharmacokinetics and efficacy of the preparation. The authors discuss in detail the numerous studies published on the safety of the preparation. They also provide a detailed analysis of current knowledge regarding the selectivity of the active ingredient. The authors conclude that the clinical efficacy and negligible toxicity of oclcitinib are outstanding compared to currently used active substances. Oclacitinib has proven to be a fastacting, safe, and effective drug in veterinary medicine for the treatment of the aforementioned conditions associated with itching. Based on its efficacy and safety profile, oclacitinib can be described as the first-line treatment for itching associated with allergic dermatitis in dogs older than 12 months and for the clinical symptoms of atopic dermatitis. Since the market launch of the oclacitinib-containing product, its safety and efficacy profile has remained consistent with that described in the product information, and the overall benefit-risk ratio of the product is positive.

Actions (login required)

Edit Item